Literature DB >> 9592197

Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review).

M J Duffy1, K McCarthy.   

Abstract

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases which catalyse degradation of diverse substrates in the extracellular matrix. The family can be loosely divided into 4 subgroups, i.e., interstitial collagenases, gelatinases, stromelysins and membrane-type MMPs. Data from model systems suggest that MMPs are involved in both stimulating tumor cell growth and promoting invasion and metastasis. Consistent with their role in tumor progression, high levels of certain MMPs have been shown to correlate with poor prognosis in different human cancers. Inhibitors of MMPs prevent or decrease tumor progression in model systems and are currently undergoing evaluation for the treatment of human cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592197     DOI: 10.3892/ijo.12.6.1343

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  20 in total

1.  Fibronectin-alpha4beta1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury.

Authors:  Carolina Moore; Xiu-Da Shen; Feng Gao; Ronald W Busuttil; Ana J Coito
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2.

Authors:  Jie Gu; Feng-kai Xu; Guang-yin Zhao; Chun-lai Lu; Zong-wu Lin; Jian-yong Ding; Di Ge
Journal:  Med Oncol       Date:  2015-01-31       Impact factor: 3.064

3.  The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action.

Authors:  Chih-Min Yang; Yi-Zih Liu; Jiunn-Wang Liao; Miao-Lin Hu
Journal:  Clin Exp Metastasis       Date:  2010-05-07       Impact factor: 5.150

4.  Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.

Authors:  S Lhoták; L J Elavathil; S Vukmirović-Popović; W C Duivenvoorden; R G Tozer; G Singh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids.

Authors:  G Giannelli; A Pozzi; W G Stetler-Stevenson; H A Gardner; V Quaranta
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

6.  Encapsulated microbubbles and echogenic liposomes for contrast ultrasound imaging and targeted drug delivery.

Authors:  Shirshendu Paul; Rahul Nahire; Sanku Mallik; Kausik Sarkar
Journal:  Comput Mech       Date:  2014-03       Impact factor: 4.014

Review 7.  Matrix metalloproteinase inhibitors: applications in oncology.

Authors:  D Yip; A Ahmad; C S Karapetis; C A Hawkins; P G Harper
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

8.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Rian Disci; Sidika Kurul; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

9.  Clinicopathological significance of maspin expression in breast cancer.

Authors:  Mi Ja Lee; Chae Hong Suh; Zhu-Hu Li
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

10.  Suppression of matrix metalloproteinase-2 via RNA interference inhibits pancreatic carcinoma cell invasiveness and adhesion.

Authors:  Ying-Hui Zhi; Mao-Min Song; Pi-Lin Wang; Tie Zhang; Zi-Yi Yin
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.